The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $2.69 in the prior trading day, Fortress Biotech Inc (NASDAQ: FBIO) closed at $2.75, up 2.23%. In other words, the price has increased by $2.23 from its previous closing price. On the day, 0.59 million shares were traded. FBIO stock price reached its highest trading level at $2.845 during the session, while it also had its lowest trading level at $2.63.
Ratios:
Our goal is to gain a better understanding of FBIO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.97 and its Current Ratio is at 2.19. In the meantime, Its Debt-to-Equity ratio is 1.22 whereas as Long-Term Debt/Eq ratio is at 1.08.
On August 04, 2022, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $6.
On October 02, 2020, The Benchmark Company started tracking the stock assigning a Buy rating and target price of $9.The Benchmark Company initiated its Buy rating on October 02, 2020, with a $9 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 29 ’25 when Fortress Biotech, Inc. sold 100,000 shares for $1.29 per share. The transaction valued at 129,000 led to the insider holds 6,122,249 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FBIO now has a Market Capitalization of 85354320 and an Enterprise Value of 76755328. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.37 while its Price-to-Book (P/B) ratio in mrq is 1.53. Its current Enterprise Value per Revenue stands at 1.232 whereas that against EBITDA is -0.961.
Stock Price History:
The Beta on a monthly basis for FBIO is 1.46, which has changed by 0.31219506 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, FBIO has reached a high of $4.20, while it has fallen to a 52-week low of $1.33. The 50-Day Moving Average of the stock is -0.13%, while the 200-Day Moving Average is calculated to be 25.69%.
Shares Statistics:
The stock has traded on average 934.94K shares per day over the past 3-months and 306280 shares per day over the last 10 days, according to various share statistics. A total of 31.01M shares are outstanding, with a floating share count of 24.52M. Insiders hold about 21.00% of the company’s shares, while institutions hold 15.19% stake in the company. Shares short for FBIO as of 1763078400 were 3976655 with a Short Ratio of 4.25, compared to 1760486400 on 3378367. Therefore, it implies a Short% of Shares Outstanding of 3976655 and a Short% of Float of 16.04.
Earnings Estimates
. The current rating of Fortress Biotech Inc (FBIO) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.
Analysts are recommending an EPS of between -$0.08 and -$0.08 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$2.12, with 2.0 analysts recommending between -$0.6 and -$3.64.
Revenue Estimates
1 analysts predict $18.8M in revenue for. The current quarter. It ranges from a high estimate of $18.8M to a low estimate of $18.8M. As of. The current estimate, Fortress Biotech Inc’s year-ago sales were $15.12M
A total of 1 analysts have provided revenue estimates for FBIO’s current fiscal year. The highest revenue estimate was $65.98M, while the lowest revenue estimate was $65.98M, resulting in an average revenue estimate of $65.98M. In the same quarter a year ago, actual revenue was $57.67MBased on 2 analysts’ estimates, the company’s revenue will be $109.53M in the next fiscal year. The high estimate is $110.8M and the low estimate is $108.25M.
